Tisch Cancer Institute at Mount Sinai
D

Leukemia Tumor Board at the Tisch Cancer Institute at Mount Sinai: Management of Polycythemia Vera

By Tisch Cancer Institute at Mount Sinai FEATURING Douglas Tremblay, John Mascarenhas, Richard Sheppard, Alan Shih, Iman Sarami
By Tisch Cancer Institute at Mount Sinai FEATURING Douglas Tremblay, John Mascarenhas, Richard Sheppard, Alan Shih, Iman Sarami
94 views
September 15, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
19:49
Rush University Medical Center

COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Feat. S. Jain
18:41
CHEST 2022 Coverage

Role of Anticoagulants and Antiplatelet Agents for Patients With COV…

Feat. V. Balasubramanian
21:20
Cleveland Clinic Rheumatology

How do I Recognize and Treat the VEXAS Syndrome?

Feat. P. Grayson
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
31:18
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Thrombosis and Anticoagulation: 2023 Update

Feat. S. Moll
24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
28:59
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Management of Simultaneous Venous and Arterial Thromboembolic Disease

Feat. J. May
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs